VACCINES

-

 VACCINES/IMMUNIZING AGENT

PHARMACOLOGIC PROFILE


 General Use

 Immune globulins provide passive immunization to infectious diseases by providing antibodies. Immunization with vaccines and toxoids containing bacterial or viral antigenic material results in endogenous production of antibodies. 


General Action 

and Information Immunity from immune globulins is rapid, but short-lived (up to 3 months). Active immunization with vaccine or toxoids produces prolonged immunity (years). 


Contraindications 

Hypersensitivity to product, preservatives, or other additives. Some products contain thimerisol, neomycin, and/or egg protein. 


Precautions

 Severe bleeding problems (IM injections). Interactions pantibody response to vaccine/toxoids and q risk of adverse reactions in patients receiving concurrent antineoplastic, immunosuppressive, or radiation therapy.


 NURSINGIMPLICATIONS

 Assessment 

● Assess previous immunization history and history of hypersensitivity. 


Potential Nursing Diagnoses

 ● Risk for infection (Indications).

 ● Deficient knowledge, related to disease process and medication regimen (Patient/Family Teaching). 


Implementation 

● Measles, mumps, and rubella vaccine, trivalent oral polio virus vaccine, and diphtheria toxoid, tetanus toxoid, and pertussis vaccine may be given concurrently.

 ● Administer each immunization by appropriate route. 


Patient/Family Teaching

 ● Inform patient/parent of potential and reportable side effects of immunization. Health care professional should be notified if patient develops fever over 39.4C (103F); difficulty breathing; hives; itching; swelling of the eyes, face, or inside of nose; sudden severe tiredness or weakness; or convulsions occur.

 ● Review next scheduled immunization with parent. Emphasize the importance of keeping a record of immunizations and dates given. 


Evaluation/Desired Outcomes 

● Prevention of diseases through active immunity.

Comments

Post a Comment

Popular posts from this blog

Tryptyr (acoltremon) – The New FDA-Approved Breakthrough for Chronic Dry Eye

-
Image
✅  What Is Tryptyr (acoltremon)? Tryptyr-acoltremon In May 2025, the U.S. Food and Drug Administration (FDA) approved Tryptyr , a new and innovative treatment for chronic dry eye disease . The active ingredient, acoltremon , works by stimulating the body’s natural tear production—making it the first drug of its kind to target the root cause of dry eyes instead of just relieving symptoms. Tryptyr belongs to a new class of therapies that activate estrogen receptors in the lacrimal glands to restore the eye's natural moisture. 🧠 Why Are People Searching for Tryptyr? Users searching for Tryptyr are typically: Suffering from persistent dry eye symptoms (burning, itching, irritation) Seeking long-term relief beyond artificial tears Interested in the latest FDA-approved treatments Looking for an alternative to Restasis or Xiidra 🔬 How Tryptyr Works: A New Approach to Dry Eye Treatment Unlike traditional eye drops, Tryptyr stimulates the lacrimal glands through...
Read more

vinorelbine - Navelbine uses _side effects

-
Image
   Vinorelbine vinorelbine(vine-oh-rel-been) Navelbine   Classification vinorelbine   Therapeutic : antineoplastics Pharmacologic : vinca alkaloids   Pregnancy Category D  Indications vinorelbine Inoperable non–small-cell cancer of the lung in ambulatory patients (alone or with cisplatin).  Action of vinorelbine Binds to a protein (tubulin) of cellular microtubules, where it interferes with microtubule assembly. Cell replication is stopped as a result (cell cycle–specific for M phase).  Therapeutic Effects of vinorelbine  Death of rapidly replicating cells, particularly malignant ones.  Pharmacokinetics vinorelbine   Absorption : IV administration results in complete bioavailability.   Distribution : Highly bound to platelets and lymphocytes.  Metabolism and Excretion : Mostlymetabolized by the liver. At least one metabolite is active. Large amounts eliminated in feces; 11% excreted unchanged by the kidneys.  ...
Read more

Keytruda (Pembrolizumab): Effective Cancer Immunotherapy Option

-
Image
  Keytruda (Pembrolizumab) Cancer treatment has witnessed a significant shift with the advent of immunotherapy , and Keytruda (Pembrolizumab) stands at the forefront of this revolution. Recent studies have shown that immunotherapy can improve survival rates in various types of cancer. Keytruda , a leading immunotherapy drug, has been instrumental in this progress, offering new hope to patients with advanced cancer. By harnessing the power of the immune system, Pembrolizumab has demonstrated its efficacy in treating a range of cancers. Key Takeaways Cancer immunotherapy has emerged as a vital treatment option. Keytruda (Pembrolizumab) is a leading drug in cancer immunotherapy . Immunotherapy treatment can significantly improve cancer survival rates. Pembrolizumab has shown efficacy across various cancer types . The role of immunotherapy in cancer treatment continues to expand. Understanding Keytruda - Pembrolizumab In the realm of cancer treatment , Pembrolizumab , or Keyt...
Read more